Triple-combination therapy did not improve prognosis in anti-MDA5 positive dermatomyositis: a multicentre longitudinal cohort study
Authors' conclusion
Our study suggests that triple-combo therapy might not be effective in improving prognosis in MDA5+ DM patients.
Study context
- Population
- Anti-MDA5-positive DM patients with interstitial lung disease (ILD), Nanjing Medical University Myositis Associated ILD (NMMI) cohort, January 2019–November 2022
- Participants
- 115 patients
- Exposure
- Triple-combo therapy vs non-triple therapy
- Outcome
- Prognosis
Main finding
As reported in the abstract
- Triple-combo therapy did not improve prognosis
Observational data: associations, not effects.
Further findings
- Triple-combo therapy linked to increased mortality rates, especially among those at high risk for rapidly progressive ILD (RP-ILD)
Original publication
Triple-combination therapy did not improve prognosis in anti-MDA5 positive dermatomyositis: a multicentre longitudinal cohort study. Clin Exp Rheumatol. Published 12 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →